

**Freedom of Information Request**

**Ref: UHB 20-105**

03 March 2020

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

**Question 1**

	<b>Rheumatology</b>	<b>Dermatology</b>	<b>Gastroenterology</b>
Is the branded biosimilar AMGEVITA listed on your formulary?	Yes	Yes	Yes

**Question 2**

Please complete the number of patients prescribed with the following products in the last 12 months within the Rheumatology, Dermatology and Gastroenterology departments:

<b>Product/place in the adalimumab therapy pathway*</b>	<b>Rheumatology</b>	<b>Dermatology</b>	<b>Gastroenterology</b>
AMGEVITA first-line	90	1	57
AMGEVITA second-line	4	3	16
HUMIRA first-line	3	0	1
HUMIRA second-line	10	1	5
HYRIMOZ first-line	0	0	0
IMRALDI first-line	205	150	176

\*How many patients receive the listed therapies as a first or second treatment once they reach the biologic/biosimilar part of their treatment pathway. For example, according to the NICE Pathway, psoriasis patients should receive topical therapy, then systemic non-biological therapy, then systemic biological therapy. We would like to know which therapies are received first and second in the biological therapy part of the pathway.

### Question 3

Please complete the table below:

Question	Department					
	Dermatology	Rheumatology			Gastroenterology	
	Psoriasis	Psoriatic arthritis	Rheumatoid arthritis	Ankylosing spondylitis	Crohn's disease	Ulcerative colitis
Are any local guidelines followed that recommend earlier use of anti-TNF biologics/ biosimilars in the treatment pathway?	No	No	No	No	No	No
Are there occasions where patients can receive adalimumab outside of NICE/SMC/AWMSG/National criteria?	No	No	No	No	No	No

### Question 4

What is the contractual agreement for seeing and treating patients with anti-TNF biologics between you and your referring CCGs/Health Boards?

Contractual agreement	Yes/No
Block contracts	No
Fixed price on a patient-by-patient basis	Yes

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Director of Corporate Governance  
University Hospitals Bristol NHS Foundation Trust

Trust Headquarters  
Marlborough Street  
Bristol  
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

### Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

**FOI Team**  
**UH Bristol NHS Foundation Trust**